Results 21 to 30 of about 142,846 (219)

CAR T Cell Therapy for Chronic Lymphocytic Leukemia: Successes and Shortcomings

Current Oncology, 2022
Chimeric antigen receptor T (CAR T) cell therapy achieved remarkable success in B-cell leukemia and lymphoma which led to its incorporation in treatment protocols for these diseases.
Zeljko Todorovic, Dusan Todorovic, Vladimir Markovic, Nevena Ladjevac, Natasa Zdravkovic, Predrag Djurdjevic, Nebojsa Arsenijevic, Marija Milovanovic, Aleksandar Arsenijevic, Jelena Milovanovic   +9 more
doaj   +1 more source

Demethylating therapy increases cytotoxicity of CD44v6 CAR-T cells against acute myeloid leukemia

Frontiers in Immunology, 2023
BackgroundCD44v6 chimeric antigen receptor T (CD44v6 CAR-T) cells demonstrate strong anti-tumor ability and safety in acute myeloid leukemia (AML). However, the expression of CD44v6 on T cells leads to transient fratricide and exhaustion of CD44v6 CAR-T ...
Ling Tang, Yingjie Kong, Haobing Wang, Ping Zou, Ting Sun, Ying Liu, Juan Zhang, Na Jin, Hanwen Mao, Xiaojian Zhu, Jue Wang, Fankai Meng, Yong You   +12 more
doaj   +1 more source

XCL1-secreting CEA CAR-T cells enhance endogenous CD8+ T cell responses to tumor neoantigens to confer a long-term antitumor immunity

Journal for ImmunoTherapy of Cancer
Background Therapeutic efficacy of carcinoembryonic antigen (CEA)-specific chimeric antigen receptor (CAR) T cells against colorectal cancer (CRC) remains limited due to the unique characteristics and distinct microenvironments of tumor tissues.
Kun Chen, Fei Zhao, Hong Zhao, Dongmei Wang, Chunfeng Qu, Zhiyuan Wu, Feifei Wang, Xing-Ning Li, Ruochan Zhang, Chentong Xiao, Yuliang Ran   +10 more
doaj   +1 more source

Universal CARs, universal T cells, and universal CAR T cells

Journal of Hematology & Oncology, 2018
Currently, the two approved T cell products with chimeric antigen receptors (CAR) are from autologous T cells. These CAR T cells approved for clinical use must be generated on a custom-made basis.
Juanjuan Zhao, Quande Lin, Yongping Song, Delong Liu   +3 more
doaj   +1 more source

Cancer Immunotherapy Using Chimeric Antigen Receptor Expressing T-Cells: Present and Future Needs of Clinical Cancer Centers

Frontiers in Immunology, 2020
Chimeric Antigen Receptor-T cells (CAR-T) are considered novel biological agents, designed to selectively attack cancer cells expressing specific antigens, with demonstrated clinical activity in patients affected with relapsed/refractory B-cell ...
Manuel Gotti, Irene Defrancesco, Mario D’Angelo, Sabrina Basso, Sabrina Basso, Luca Crotto, Alfredo Marinelli, Alfredo Marinelli, Cristina Maccalli, Vincenzo Iaconianni   +9 more
doaj   +1 more source

Delivery of CD47 blocker SIRPα-Fc by CAR-T cells enhances antitumor efficacy

Journal for ImmunoTherapy of Cancer, 2022
Background Chimeric antigen receptor (CAR) T cell therapy has been successfully applied in treating lymphoma malignancies, but not in solid tumors. CD47 is highly expressed on tumor cells and its overexpression is believed to inhibit phagocytosis by ...
Bolan Yu, Huanpeng Chen, Yuying Yang, Yuqing Deng, Fengjiao Wei, Qingyu Zhao, Yongqi Liu, Zhonghua Liu, Zhaofeng Huang   +8 more
doaj   +1 more source

ABL kinase‐dependent phosphorylation of SH proteins promotes their direct interaction with CRK family SH2 domains

FEBS Letters, EarlyView.
CT10 regulator of kinase (CRK) and CRK‐Like (CRKL) are signaling adaptors driving cell adhesion, motility, differentiation, and proliferation. SH2‐domain containing (SH) proteins are enriched in YXXP motifs which when phosphorylated create preferred binding sites for CRK family SH2 domains.
Phoebe M. Cousens, Brendan W. Chandler, Anna M. Schmoker, Jaye L. Weinert, Charlotte A. Kearns, Warren T. Yacawych, Amila Šemić, Alicia M. Ebert, Bryan A. Ballif   +8 more
wiley   +1 more source

Monitoring of Circulating CAR T Cells: Validation of a Flow Cytometric Assay, Cellular Kinetics, and Phenotype Analysis Following Tisagenlecleucel

Frontiers in Immunology, 2022
Chimeric antigen receptor (CAR) T cell therapy is a potent new treatment option for relapsed or refractory hematologic malignancies. As the monitoring of CAR T cell kinetics can provide insights into the activity of the therapy, appropriate CAR T cell ...
Andreas Peinelt, Andreas Peinelt, Melanie Bremm, Melanie Bremm, Hermann Kreyenberg, Hermann Kreyenberg, Claudia Cappel, Claudia Cappel, Julia Banisharif-Dehkordi, Julia Banisharif-Dehkordi, Stephanie Erben, Stephanie Erben, Eva Rettinger, Eva Rettinger, Andrea Jarisch, Andrea Jarisch, Roland Meisel, Paul-Gerhardt Schlegel, Olaf Beck, Gesine Bug, Jan-Henning Klusmann, Thomas Klingebiel, Sabine Huenecke, Sabine Huenecke, Peter Bader, Peter Bader   +25 more
doaj   +1 more source

Structure‐forward targeting of claudins with synthetic binders

FEBS Letters, EarlyView.
Claudins form the paracellular barriers between epithelial and endothelial tissues at tight junctions and are targets for molecular binders with the goal of modulating barrier permeability. Claudin‐binding molecules are relevant in drug delivery or in altering claudin interactions with disease‐causing proteins.
Alex J. Vecchio
wiley   +1 more source

A second‐generation CD38‐CAR‐T cell for the treatment of multiple myeloma

Cancer Medicine, 2023
Background Multiple myeloma (MM) is an aggressive plasma cell malignancy, causing a number of deaths worldwide every year. Chimeric antigen receptor (CAR) transduced T‐cell therapy has been a promising immunotherapy against hematological malignancies ...
Hongwen Li, Jing Li, Jiazhuo Wu, Zhuangzhuang Shi, Yuyang Gao, Wenting Song, Jiwei Li, Zhaoming Li, Mingzhi Zhang   +8 more
doaj   +1 more source